within Pharmacolibrary.Drugs.ATC.C;

model C05AX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.016666666666666666,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>The ATC group C05AX03 refers to combination preparations used as vasoprotectives for treatment of hemorrhoids and varicose veins, often formulated as topical creams, ointments, or suppositories containing various agents such as corticosteroids, anesthetics, and vasoconstrictors. These are primarily used for symptomatic relief of hemorrhoids and are still in use today in several countries, though specific formulations may differ.</p><h4>Pharmacokinetics</h4><p>No direct published pharmacokinetic data available for unspecified combination preparations under ATC code C05AX03; values estimated based on typical topical administration of combination hemorrhoidal agents in adults.</p><h4>References</h4><ol><li><p>Altman, R, et al., &amp; Young, C (2015). Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. <i>Drugs</i> 75(8) 859–877. DOI:<a href=&quot;https://doi.org/10.1007/s40265-015-0392-z&quot;>10.1007/s40265-015-0392-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25963327/&quot;>https://pubmed.ncbi.nlm.nih.gov/25963327</a></p></li><li><p>Abdalla, MI, &amp; Herfarth, H (2016). Budesonide for the treatment of ulcerative colitis. <i>Expert opinion on pharmacotherapy</i> 17(11) 1549–1559. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2016.1183648&quot;>10.1080/14656566.2016.1183648</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27157244/&quot;>https://pubmed.ncbi.nlm.nih.gov/27157244</a></p></li><li><p>Parisi, N, et al., &amp; Lane, ME (2016). Topical delivery of hexamidine. <i>International journal of pharmaceutics</i> 506(1-2) 332–339. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2016.04.069&quot;>10.1016/j.ijpharm.2016.04.069</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27130367/&quot;>https://pubmed.ncbi.nlm.nih.gov/27130367</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C05AX03;
